Aims: To investigate candidate genes in peripheral blood mononuclear cell (PBMC) that are associated with early onset severe preeclampsia (ES-PE) and to describe candidate genes function using microarrays and real-time polymerase chain reaction (PCR). Methods: PBMC RNA was extracted from six patients with ES-PE and five uncomplicated pregnancies. The HG_U133 plus 2.0 Affymetrix GeneChips that represented 47,000 genes were used to measure gene expression in each sample. Significance analysis of microarray identified potential signature genes characterizing ES-PE vs. uncomplicated pregnancies. Eight genes were selected for confirmation by real-time PCR of 32 patients with ES-PE and 24 uncomplicated pregnancies, matched for maternal age, parity, race and gestational weeks. Results: Using a whole-genome approach to study the molecular determinants of ES-PE, 72 genes were found to be differentially expressed between cases and controls, including 38 up-regulated genes and 34 downregulated genes in the group of ES-PE. Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), aldo-keto reductase family 1, member C3 (AKR1C3), churchill domain containing 1 (CHURC1), and solute carrier family 25, member 13 (SLC25A13) were validated to be down-regulated in the patients with ES-PE by real-time PCR. 
Introduction
Preeclampsia (PE) is a common pregnancy-specific syndrome (3-5%) of first pregnancies, and ranks among the leading causes of maternal and perinatal morbidity and mortality (12%) worldwide w7x. According to whether the clinical manifestations occur before or after 32 weeks of gestation, PE was classified into early and late onset type w15x. Large epidemiological studies have demonstrated that women with a history of early onset severe preeclampsia (ES-PE) show an increase risk of cardiovascular disease w2x. The likelihood that PE will recur is almost 50% for ES-PE w4x, whereas it is 10%-20% for PE near term w3x. The ES-PE is regarded as more dangerous than late onset severe PE and of a different etiology. Despite the urgent need to diagnose PE early and to have a non-invasive tool for prognosis and treatment monitoring, no predictive test is available to identify pregnant women who will subsequently develop PE and which of those may develop the early or late type of the syndrome. Thus a standardized blood-based test capable of detecting individuals at risk for ES-PE would represent a major advance in clinical care.
Microarray studies of disease have been based on RNA derived from biopsy/tissue samples. The systematic study of the gene expression patterns of placenta revealed differences in gene expression patterns associated with preeclampsia w12x. However, blood samples are less invasive, allow for a larger sample size, and make feasible repeated sampling to monitor disease progression. Several studies have shown that total RNA derived from circulating blood can distinguish between control subjects and patients with various disease types w6x. Fetal DNA or RNA testing of preeclampsia is being investigated however, and their clinical utility is still unclear. In this study, we analyzed blood cell-derived RNA for patterns of differential gene expression of Chinese Han population that could serve as indicators of normal and abnormal biological processes and provide information on mechanisms of ES-PE.
Materials and methods

Subjects and sample acquisition
Informed consent was obtained from each subject in accordance with the protocol approved by the Human Studies Committee of Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Maternal blood samples from 67 singleton pregnancies (38 ES-PE and 29 uncomplicated pregnancies controls) were collected between September 2006 and October 2008. We randomly selected 6 ES-PE and 5 controls to perform oligonucleotide array. After that, the remaining 32 ES-PE and 24 controls were used as samples to validate gene expression using real-time PCR. ES-PE was defined as new onset hypertension (systolic blood pressure G160 mm Hg or diastolic blood pressure G110 mm Hg at least twice 6 h apart) and proteinuria (2 g per 24-h period or 2-4q on random urine dipstick in the acute setting) after 20 weeks of gestation with severe criteria according to guidelines published by the American College of Obstetricians and Gynecologists in women who required delivery between 24 and 32 gestation weeks because of PE w1x. The control group comprised healthy pregnant women in gestational weeks 24-32 recruited during a routine visit to an antenatal clinic. Only those whose pregnancy continued normally and resulted in a full-term delivery of a healthy child with normal weight were included in the study. Only women with the aforementioned criteria within their first pregnancies were included. Women with a concurrent diagnosis of an upper urinary tract infection, chronic hypertension (hypertension before the 20 th week of gestation), diabetes mellitus, or pre-exiting renal disease were not included. None of the control had a family history of PE.
RNA extraction and microarray procedures
Blood samples (8 mL) were drawn into EDTA Vacutainer tubes (Becton Dickinson) by routine venipuncture, put immediately on 48C) and transferred to the laboratory within 2 h for blood processing. Total RNA was isolated from lymphocytes with Trizol (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. The RNA preparations were then DNase treated and purified with the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA quality was assessed on an Agilent 2100 Bioanalyzer RNA 6000 NanoChip (Agilent, Palo Alto, CA), and quantity was determined by absorbance at 260 nm in a Beckman Coulter DU640 spectrophotometer. With 2.5 mg of purified total RNA, samples were prepared for cRNA amplification and hybridization, as previously described w18x. Microarray analysis was performed overnight by using high-density human genome U133 plus 2.0 GeneChips (HG-U133 plus 2.0; Affymetrix, Santa Clara, CA). HG-U133 plus 2.0 GeneChip contains 54,646 25-mer probe sets, represents about 47,000 genes. Subsequently, the chips were scanned with an Affymetrix GeneChip Scanner 3000, and the data were extracted by GeneChip Operating software Version 1.4(GCOS1.4) (Affymetrix Inc.). Signal intensities were centered to the 50 th percentile of each chip, and for each individual probe set, to the median intensity of each specific subset first, to minimize possible technical bias, and then to the whole sample set. Only genes identified by the GCOS software as ''present'' or ''marginal'' in all samples were analyzed.
Microarray data analysis
Raw data without normalization were analyzed by significance analysis of microarrays (SAM). Normalized data were first filtered to eliminate the genes which were absent in all experimental conditions and replicates. Then, parametric analysis assuming unequal variance was applied to test statistical significance. Fold-ratios were derived by comparing normalized data between controls and preeclampsia. Only genes that are up-or downregulated more than two-fold were filtered. Genes were deemed statistically different between groups if they had an adjusted P-0.05 and an average fold-change difference of )2. Averagelinkage hierarchical clustering analysis using centered correlation analysis and visualization was performed using the CLUSTER and TREEVIEW programs.
Go classification
Gene ontology analysis was performed using an online data base known as the Molecular Analysis System (MAS, http:// bioinfo.capitalbio.com/mas/). Molecular functions, biological processes and biological pathways up/down-regulated by ''signature'' genes of the ES-PE were identified and the statistical significance of up/down-regulation was quantified by a random overlapping P-value using the binomial test with all the genes represented by the Affymetrix ᮋ HG-U133 plus 2.0 microarrays as the reference list. From the 38 blood genes overexpressed and 34 blood genes under-expressed in ES-PE, we selected a set of 8 genes to be evaluated by quantitative realtime RT-PCR. We used the following criteria to make our selection: P, fold change, discrimination power form ROC curve analysis between ES-PE patients and the control group, and the function of the gene.
Design of specific primers
Oligonucleotide primers specific for down-regulated genes killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), aldo-keto reductase family 1, member C3 (AKR1C3), churchill domain containing 1 (CHURC1), solute carrier family 25, member 13 (SLC25A13) and up-regulated genes calponin2 (CNN2), V-set and immunoglobulin domain containing 4 (VSIG4), matrix metallopeptidase 8 (MMP8), proteasome 26S subunit ATPase 5 (PSMC5) isoforms were designed using Primer Expressீ Version 2.0 software (PE Applied Biosystems, Inc., Foster City, CA). Beta-actin is chosen as an endogenous control/ reference. Sequences of the primer sets used for real-time PCR verification are listed in Table 1 .
Validation of gene expression data by quantitative RT-PCR
The remaining 32 ES-PE and 24 controls were enough to perform SYBR Green I real-time PCR assay validation. First-strand cDNA was synthesized from 8 mg of total RNA using the ABI High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) on a Perkin-Elmer (Wellesley, MA) DNA Thermal Cycler according to the manufacturer's protocol. The resulting cDNA was subjected to a 40-cycle PCR amplification followed by real-time PCR reaction using the Power SYBR ᮋ Green PCR Master Mix Kit protocol (Applied Biosystems, P/N4367659). Four replicates were run for each gene for each sample in a final volume of 20 mL, and multiple negative water blanks were included in every analysis. Amplification efficiency and specificity of the primer pairs were determined using serial dilution of reference cDNA generated from a normal blood RNA pool with confirmation on agarose gel to ensure that the values Values are expressed as mean"SD and were analyzed with one-way analysis of variance; significant at P-0.05. BMIsbody mass index.
were within linear range and the amplification efficiency was approximately equal for each of the target gene tested. SYBR Green PCR assays were performed on cDNA samples in 96-well optical plates in an ABI PRISM 7300 Sequence Detection System (Applied Biosystems, Foster City, CA). Analysis of relative gene expression data was performed using the comparative CT method (DDCT) with b-actin (ACTB) as an endogenous control/ reference assay. Cycling parameters for a two-step PCR were 958C for 10 min, 1 cycle, then 608C for 1 min, 958C for 15 s, 40 cycles. The confirmation of specific amplification and lack of primer dimmer formation were determined by calculated melting dissociation curve. The real-time PCR products were examined in 2% agarose gel.
Statistical analysis
All values are expressed as mean"SD. Statistical significance (defined as P-0.05) of clinical characteristics of ES-PE and normal control subjects was evaluated using one-way analysis of variance. P-values of different gestational weeks (-28 gestation weeks and 28-32 gestation weeks) were calculated by Fisher's Exact test. All statistical analyses were performed with SPSS 12.0 (SPSS Inc, Chicago, IL).
Results
Gene expression signature of early onset severe preeclampsia in peripheral leukocytes
Patients were recruited from among those who presented with ES-PE of Beijing Obstetrics and Gynecology Hospital. To explore whether we can identify a gene expression signature of ES-PE from peripheral blood samples, 38 patients and 29 controls were analyzed in this study. Six patients and five controls were analyzed using the Affymetrix ᮋ HG-U133 plus 2.0 chips representing 47,000 individual human genes, which showed significant differences in the expression levels of 72 genes. The demographic and pregnancy characteristics of each group are summarized in Table 2 . Patients with ES-PE and controls were similar in maternal age, pre-pregnancy body mass index, parity, and race. All subjects were of Chinese Han origin. According to different gestational weeks, we classified ES-PE into two groups: -28 gestation weeks (ns10, 26.4%) and 28-32 gestation weeks (ns28, 73.6%). The high risk of hypoproteinemia, high blood viscosity, proteinuria )5 g, abnormal renal function, thrombocytopenia, placental abruption, peritoneal fluid, fetal growth restriction, neonatal asphyxia and neonatal death were observed in the group of -28 gestation weeks (P-0.05, data not shown).
Using SAM analysis, 72 genes were differentially expressed between case and control groups based on the following criteria: (1) false discovery rate (FDR) -5.4%; (2) average fold change )2.0. Thirty-eight genes were over-expressed and 34 genes were underexpressed in the patient group (Table 3) . We also did cluster analysis on the 72 genes to arrange the samples according to similarities in gene expression patterns as described previously. Hierarchical cluster analysis of the Compared with early onset severe preeclampsia, women with normotensive pregnancies have an 83.7-fold increase in AKR1C3, an 11.1-fold increase in CHURC1, a 23.2-fold increase in KIR3DL2 and a 20.7-fold increase in SLC25A13.
above-mentioned, differentially expressed genes resulted in a clear separation of the ES-PE from the healthy controls. MAS in GenMAPP showed that after correction for multiple hypothesis testing there were statistically significant enrichments of transcripts within the 38 genes that are up-regulated in the ES-PE, displaying extracellular space (Ps9.0E-6), cell proliferation (Ps0.0016), smooth muscle contraction (Ps0.01). The over-expressed genes included CNN2, VSIG4, PSMC5 and MMP8. On the other hand, statistically significant association of the 34 downregulated genes in ES-PE was observed with pathways such as natural killer cell mediated cytotoxicity (Ps0.00), antigen processing and presentation (Ps6.3E-5) and arachidonic acid metabolism (Ps0.05), suggesting immune response associated with the circulating cells of ES-PE. The significant down-regulated genes included KIR3DL2, AKR1C3, CHURC1, SLC25A13.
SYBR green I real-time PCR validation
To further validate the preeclampsia-status classifier genes, we determined expression levels of the 8 preeclampsia-status classifier genes using the SYBR Green I real-time PCR methodology on 56 samples for which enough RNA was available. The initially identified candidate genes were assayed by real-time PCR on a sample set of 32 ES-PE and 24 controls. To control for technical variation, we performed the comparative Ct method between a candidate gene and a housekeeping gene (DC T sCt of target gene-Ct of housekeeping gene, DDC T sDC T of target gene-DC T of housekeeping gene) to assess differences between the tested experimental groups. We found statistically significant differences in the expression of AKR1C3, KIR3DL2, SLC25A13, CHURC1 in ES-PE, which selected from the array results. For CNN2, VSIG4, MMP8 and PSMC5, the findings were inconsistent with microarray (Table 4) . We stress here that the true specificity of the assay will require the inclusion of patients with ES-PE pathology other than the disease.
Discussion
It is increasingly evident that a gene plays an important role in the development of preeclampsia. We report here the feasibility of using gene expression profiling of circulating blood cells to identify novel blood biomarker in ES-PE patients. Our study suggests several points. First, through a whole-genome gene expression profiling analysis of cases and controls, we have identified a 4-gene signature in peripheral blood cells that distinguishes early onset severe preeclamptic patients from controls. Significant down-regulation of KIR3DL2, AKR1C3, CHURC1 and SLC25A13 were observed from microarray analysis and further validated by SYBR Green I realtime RT-PCR assays. Moreover, this investigation also suggested that many of the biological pathways such as natural killer cell mediated cytotoxicity, antigen processing and presentation and arachidonic acid metabolism have been associated with development of preeclampsia. Although our primary interest was ES-PE, we believe that the approach shown in our study can be used to identify biomarkers in other diseases.
Many clinical studies correlated alterations in expression of individual genes with preeclampsia, often with contradictory results. Han et al. have report that the expression of caspase-10 and death receptor 3 (DR-3) was significantly increased, whereas insulin-like growth factor binding protein-3 (IGFBP-3) was strongly downregulated w5x. Okazaki et al. showed that the mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating in blood of women with preeclampsia w11x. Surprisingly, none of these genes are present in our set of 72 genes. This could be due to the fact that we determine gene expression at the period of early onset of the disease, whereas most previous studies did not confine the time of onset and the origin of samples. Killer cell immunoglobulin-like receptors (KIRs) are of particular interest in the context of preeclampsia. They have been divided into distinct groups, depending on the number of external immunoglobulin domains (2D or 3D). The presence of a long cytoplasmatic tail with two immune tyrosinebased inhibitory motifs (ITIMs) allows the transduction of inhibitory signals and characterizes the inhibitory KIRs (2DL, 3DL), whereas the presence of short cytoplasmatic tails corresponds to the activating KIR receptors (2DS, 3DS) w19x. KIRs are glycoproteins expressed on the cell surface of natural killer (NK) and subsets of T cells. A well-described way of NK cells to recognize target cells is surveillance for cells with reduced levels of MHC class I molecules, a phenotypic change that frequently occurs in tumor variants and virally infected cells. Different inhibitory KIRs are specific for HLA-A (KIR3DL2), HLA-B (KIR3DL1), and different subgroups of HLA-C (KIR2DL1-3). Defective placentation is the likely pathogenesis of preeclampsia w10x. This involves reduced trophoblast invasion into both the decidua and spiral arteries. The loose plugs of endovascular trophoblast that normally limit the maternal circulation to the placenta may be incomplete w8x. The correlation between the development of ES-PE and primigravidae is suggestive of a defect in fetal-maternal immune recognition. Our work provides molecular evidence that this immune problem may be mediated by defective KIR3DL2 expression. We observed reduced KIR3DL2 transcription levels in ES-PE and propose that lacking killer-inhibitory receptors for self-HLA class I molecules results in abnormal activation of NK/T cells, weaken inhibitory signaling, powering NK cells recognition. Trophoblasts lacking KIR3DL2 are vulnerable to attack by the maternal immune system, thereby developing vessels which cannot adequately nourish the developing placenta.
Aldo-Keto Reductases (AKRs) are a superfamily of NAD(P)H linked oxidoreductases that catalyze the NADP(H)-dependent reduction of a wide variety of substrates. AKR1C3 possesses 3a-HSD, 17b-HSD, 20a-HSD and prostaglandin (PG) F synthase activities and catalyzes androgen, estrogen, progesterone and PG metabolism w13x. AKR1C3, therefore, has the capability of regulating ligand access to multiple nuclear receptors including the androgen receptor (AR), estrogen receptor, progesterone receptor and peroxisome proliferators activated receptor gamma (PPARg) in endocrine peripheral tissues. AKR1C3 may prevent PPARg signaling by preventing the formation of its ligand 15d-PGJ 2 and by stimulating the phosphorylation of the receptor, leading to a pro-proliferative response. AKR1C3 is uniquely positioned to reduce PGH 2 and PGD 2 to yield PGF epimers leading to the inactivation of PPARg upon exposure to oxidative stress. Moreover, since the PGF epimers bind to the F-series-prostanoid (FP) receptor, this could lead to activation of NFkB and propagation of an inflammatory response involving induction of COX-2. Severe Deoxycorticosterone (DOC) excess as is seen in 17a-and 11b-hydroxylase deficiencies causes hypertension, and moderate DOC overproduction in late pregnancy is associated with hypertension. Excess DOC will bind to the mineralocorticocoid receptor causing hypertension in pregnancy when AKR1C3 decreases w16x. AKR1C3 protects the mineralocorticoid receptor from activation by DOC in mineralocorticoid target cells of the kidney and colon. Oxidative stress may mediate endothelial cell dysfunction and contribute to the pathophysiology of preeclampsia as there is evidence of increased prooxidant activity formation along with decreased antioxidant protection preeclampsia. Higher placental NADPH oxidase activity has been reported in women with early-onset preeclampsia as compared with those with late-onset of disease which is consistent with the concept that earlyonset preeclampsia is more dependent on placental dysfunction than the later-onset disease. Down-regulated AKR1C3 expression in maternal blood may result in lacking of anti-oxidant response elements, therefore, reactive oxygen species produced under conditions of oxidative stress, attack polyunsaturated fatty acids to form a series of lipid peroxides which are implicated in the patho-genesis of atherosclerotic plaques. The lipid peroxides further damage the structure and function of vascular endothelial cell.
No biological function of Churchill (ChCh) in relation to preeclampsia is known to date. ChCh is a zinc-containing protein involved in neural induction during embryogenesis. ChCh was discovered in a differential screen for neural inducing factors present in chick embryos w9x. ChCh was identified as a late FGF response gene that is upregulated within 4-5 h of signaling from both the organizer and FGF and shows no indication of down-regulation in the presence of BMP. It is difficult to speculate on a preeclampsia-promoting function of CHURC1. Zinc finger proteins are known to participate in a variety of cellular activities including development, differentiation, and tumor suppression and though originally determined to be DNA binding proteins, there is increasing evidence that zinc finger proteins also recognize RNA and participate in protein-protein and protein-lipid interactions.
The SLC25A13 gene consists of 18 exons and encodes a liver type mitochondrial aspartate-glutamate carrier named citrin, which plays an important role in malate-aspartate NADH shuttling, urea synthesis, and gluconeogenesis. In humans, loss-of-function mutations in the SLC25A13 gene encoding citrin cause both adultonset type II citrullinemia (CTLN2) and neonatal intrahepatic cholestasis (NICCD), collectively referred to as human citrin deficiency w17x. The urea cycle processes excess nitrogen to make urea, which is excreted in urine. An adequate supply of aspartate must be transported out of mitochondria to participate in a process called the urea cycle which is a sequence of chemical reactions that takes place in liver cells. These reactions process excess nitrogen that is generated as the body uses proteins. Research reveals that loss of citrin first causes deficiency of aspartate in the cytosol, which results in an increase in cytosolic NADH/NAD(q) ratio and then activation of fatty acid synthesis pathway to compensate the aberrant ratio w14x. SLC25A13 expression is down-regulated in the ES-PE. As a result of citrin deficiency, arginine cannot be supplied from the urea cycle which is the enzymesubstrate complex of endothelia nitric oxide synthase (eNOS), therefore, nitrogen monoxidum cannot generate enough from eNOS.
The VSIG4, CNN2, MMP8 and PSMC5 yielded inconsistent results. For VSIG4, discordant observations between the array hybridization (up 3.84-fold) and realtime PCR (significantly down 12-fold, Ps0.003) were made for ES-PE. We have also observed, in the microarray, 2-fold up-regulations were for CNN2, 2.3-fold for MMP8 and 2-fold for PSMC5. In quantitative PCR, however, we found a significantly decreased expression level.
From these data, we have identified AKR1C3, CHURC1, SLC25A13 and KIR3DL2 which might be involved in the molecular mechanisms underlying the progression of ES-PE, and highlight potential targets for therapeutic intervention.
